TLSA logo

TLSA Tiziana Life Sciences Ltd

NASDAQ Global Market · Biotechnology · Healthcare

$0.81
+0.16 (+24.23%)

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colit…

Market Cap: $103.06Mwww.tizianalifesciences.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
57
3 mentions
—
60d
50
6 mentions
—
90d
49
8 mentions
—
news: 8

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 1Sell 0Strong Sell 0

Revenue

$0.00-100.00%
$-41.0K$40.2K$121.3K$202.5K
Dec 2006Jun 2026

Analyst Estimates

FY2025
$-0.16
$-0.16–$-0.16
1 analysts
FY2026
$-0.17
$-0.17–$-0.17
1 analysts
FY2027
$-0.19
$-0.19–$-0.19
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Ivor R. Elrifi
Sector
Healthcare
Industry
Biotechnology
Employees
10
Beta
0.46
Country
GB
Piotroski score
1 / 9 (Weak)
Altman Z-score
-11.77
www.tizianalifesciences.com